Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The 2017 Oxford University iGEM team have just returned from the competition in Boston with not only a Gold medal but also the extremely competitive award for Best Diagnostics Project in the Undergraduate category. In addition they were nominated for five further awards for best presentation, wiki, model, integrated human practices and best applied design.

The iGEM competition challenges interdisciplinary teams of students to spend the summer working on applying Synthetic Biology to address real world issues. The undergraduates drive the project from beginning to end. This year’s team of 6 female and 6 male students, from Biochemistry, Engineering, Biology and Medicine, set out to develop a cheap and reliable diagnostic for Chagas disease. Chagas disease is a parasitic infection affecting millions of poor people in South America. If is diagnosed early it can be treated, but can be fatal if treatment is delayed.

The team interacted with stakeholders both in the UK and in the affected regions to guide their project. They used mathematical modelling to predict the behaviour of, and optimise, the genetic circuitry for their device before producing and testing various components in the laboratory. They also carried out iterations of designs and costings for their device and considered the potential benefits and issues around its use in the field.

Finally, the project culminated in Boston where they competed with more than 300 other teams from across the world, presenting their design and results to more than 3000 people at the Jamboree.

Find out more about their project (external link)

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.